Cargando…

Opportunities for Ferroptosis in Cancer Therapy

A critical hallmark of cancer cells is their ability to evade programmed apoptotic cell death. Consequently, resistance to anti-cancer therapeutics is a hurdle often observed in the clinic. Ferroptosis, a non-apoptotic form of cell death distinguished by toxic lipid peroxidation and iron accumulatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujihara, Kenji M., Zhang, Bonnie Z., Clemons, Nicholas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235304/
https://www.ncbi.nlm.nih.gov/pubmed/34205617
http://dx.doi.org/10.3390/antiox10060986
_version_ 1783714285457768448
author Fujihara, Kenji M.
Zhang, Bonnie Z.
Clemons, Nicholas J.
author_facet Fujihara, Kenji M.
Zhang, Bonnie Z.
Clemons, Nicholas J.
author_sort Fujihara, Kenji M.
collection PubMed
description A critical hallmark of cancer cells is their ability to evade programmed apoptotic cell death. Consequently, resistance to anti-cancer therapeutics is a hurdle often observed in the clinic. Ferroptosis, a non-apoptotic form of cell death distinguished by toxic lipid peroxidation and iron accumulation, has garnered substantial attention as an alternative therapeutic strategy to selectively destroy tumours. Although there is a plethora of research outlining the molecular mechanisms of ferroptosis, these findings are yet to be translated into clinical compounds inducing ferroptosis. In this perspective, we elaborate on how ferroptosis can be leveraged in the clinic. We discuss a therapeutic window for compounds inducing ferroptosis, the subset of tumour types that are most sensitive to ferroptosis, conventional therapeutics that induce ferroptosis, and potential strategies for lowering the threshold for ferroptosis.
format Online
Article
Text
id pubmed-8235304
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82353042021-06-27 Opportunities for Ferroptosis in Cancer Therapy Fujihara, Kenji M. Zhang, Bonnie Z. Clemons, Nicholas J. Antioxidants (Basel) Perspective A critical hallmark of cancer cells is their ability to evade programmed apoptotic cell death. Consequently, resistance to anti-cancer therapeutics is a hurdle often observed in the clinic. Ferroptosis, a non-apoptotic form of cell death distinguished by toxic lipid peroxidation and iron accumulation, has garnered substantial attention as an alternative therapeutic strategy to selectively destroy tumours. Although there is a plethora of research outlining the molecular mechanisms of ferroptosis, these findings are yet to be translated into clinical compounds inducing ferroptosis. In this perspective, we elaborate on how ferroptosis can be leveraged in the clinic. We discuss a therapeutic window for compounds inducing ferroptosis, the subset of tumour types that are most sensitive to ferroptosis, conventional therapeutics that induce ferroptosis, and potential strategies for lowering the threshold for ferroptosis. MDPI 2021-06-21 /pmc/articles/PMC8235304/ /pubmed/34205617 http://dx.doi.org/10.3390/antiox10060986 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Perspective
Fujihara, Kenji M.
Zhang, Bonnie Z.
Clemons, Nicholas J.
Opportunities for Ferroptosis in Cancer Therapy
title Opportunities for Ferroptosis in Cancer Therapy
title_full Opportunities for Ferroptosis in Cancer Therapy
title_fullStr Opportunities for Ferroptosis in Cancer Therapy
title_full_unstemmed Opportunities for Ferroptosis in Cancer Therapy
title_short Opportunities for Ferroptosis in Cancer Therapy
title_sort opportunities for ferroptosis in cancer therapy
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235304/
https://www.ncbi.nlm.nih.gov/pubmed/34205617
http://dx.doi.org/10.3390/antiox10060986
work_keys_str_mv AT fujiharakenjim opportunitiesforferroptosisincancertherapy
AT zhangbonniez opportunitiesforferroptosisincancertherapy
AT clemonsnicholasj opportunitiesforferroptosisincancertherapy